Models of Parkinson's disease
Identifieur interne : 004038 ( Main/Exploration ); précédent : 004037; suivant : 004039Models of Parkinson's disease
Auteurs : Michael Orth [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-07.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animal, Animals, Apoptosis (drug effects), Apoptosis (genetics), Cell culture, Cells, Cultured (drug effects), DNA Mutational Analysis, Disease Models, Animal, Dopamine Agents (toxicity), Human, Humans, Mice, Mice, Knockout, Mice, Transgenic, Models, Models, Genetic, Nerve Tissue Proteins (genetics), Oxidopamine (toxicity), Parkinson disease, Parkinson's disease, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (genetics), Risk Factors, Rotenone (toxicity), Substantia Nigra (drug effects), Synucleins, cell culture, disease models, transgenic mice.
- MESH :
- chemical , genetics : Nerve Tissue Proteins.
- chemical , toxicity : Dopamine Agents, Oxidopamine, Rotenone.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Synucleins.
- chemically induced : Parkinsonian Disorders.
- drug effects : Apoptosis, Cells, Cultured, Substantia Nigra.
- genetics : Apoptosis, Parkinsonian Disorders.
- Animals, DNA Mutational Analysis, Disease Models, Animal, Humans, Mice, Mice, Knockout, Mice, Transgenic, Models, Genetic, Risk Factors.
Abstract
Parkinson's disease (PD) is a heterogenous disease likely to be caused by more than one specific aetiological factor. In rare familial cases of PD with similar clinical features to the idiopathic form of the disease, the underlying genetic cause has been identified. These PD‐associated genes have been manipulated to create animal and cell culture models of the disease that have helped to further our understanding of the pathogenesis of PD, particularly concerning causes of the selective loss of dopaminergic neurons at the molecular level. In addition, these models will aid the future development of rational therapeutic strategies. This study briefly reviews toxin‐induced models and the genetics of PD. It focuses on recently developed animal models of PD, as well as in vitro approaches to model the disease. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10447
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001083
- to stream Istex, to step Curation: 001083
- to stream Istex, to step Checkpoint: 002968
- to stream PubMed, to step Corpus: 003759
- to stream PubMed, to step Curation: 003759
- to stream PubMed, to step Checkpoint: 003730
- to stream Ncbi, to step Merge: 000A92
- to stream Ncbi, to step Curation: 000A92
- to stream Ncbi, to step Checkpoint: 000A92
- to stream Main, to step Merge: 005C61
- to stream PascalFrancis, to step Corpus: 002442
- to stream PascalFrancis, to step Curation: 000879
- to stream PascalFrancis, to step Checkpoint: 002405
- to stream Main, to step Merge: 005F51
- to stream Main, to step Curation: 004038
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Models of Parkinson's disease</title><author><name sortKey="Orth, Michael" sort="Orth, Michael" uniqKey="Orth M" first="Michael" last="Orth">Michael Orth</name></author><author><name sortKey="Tabrizi, Sarah J" sort="Tabrizi, Sarah J" uniqKey="Tabrizi S" first="Sarah J." last="Tabrizi">Sarah J. Tabrizi</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:82545F26DC87C73EF84D8002EF2A4FE27E54BDB2</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10447</idno><idno type="url">https://api.istex.fr/document/82545F26DC87C73EF84D8002EF2A4FE27E54BDB2/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001083</idno><idno type="wicri:Area/Istex/Curation">001083</idno><idno type="wicri:Area/Istex/Checkpoint">002968</idno><idno type="wicri:doubleKey">0885-3185:2003:Orth M:models:of:parkinson</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:12815651</idno><idno type="wicri:Area/PubMed/Corpus">003759</idno><idno type="wicri:Area/PubMed/Curation">003759</idno><idno type="wicri:Area/PubMed/Checkpoint">003730</idno><idno type="wicri:Area/Ncbi/Merge">000A92</idno><idno type="wicri:Area/Ncbi/Curation">000A92</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A92</idno><idno type="wicri:doubleKey">0885-3185:2003:Orth M:models:of:parkinson</idno><idno type="wicri:Area/Main/Merge">005C61</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:03-0458945</idno><idno type="wicri:Area/PascalFrancis/Corpus">002442</idno><idno type="wicri:Area/PascalFrancis/Curation">000879</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002405</idno><idno type="wicri:doubleKey">0885-3185:2003:Orth M:models:of:parkinson</idno><idno type="wicri:Area/Main/Merge">005F51</idno><idno type="wicri:Area/Main/Curation">004038</idno><idno type="wicri:Area/Main/Exploration">004038</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Models of Parkinson's disease</title><author><name sortKey="Orth, Michael" sort="Orth, Michael" uniqKey="Orth M" first="Michael" last="Orth">Michael Orth</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical and Experimental Epilepsy, Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Tabrizi, Sarah J" sort="Tabrizi, Sarah J" uniqKey="Tabrizi S" first="Sarah J." last="Tabrizi">Sarah J. Tabrizi</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurodegenerative Diseases, Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-07">2003-07</date><biblScope unit="vol">18</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="729">729</biblScope><biblScope unit="page" to="737">737</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">82545F26DC87C73EF84D8002EF2A4FE27E54BDB2</idno><idno type="DOI">10.1002/mds.10447</idno><idno type="ArticleID">MDS10447</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animal</term><term>Animals</term><term>Apoptosis (drug effects)</term><term>Apoptosis (genetics)</term><term>Cell culture</term><term>Cells, Cultured (drug effects)</term><term>DNA Mutational Analysis</term><term>Disease Models, Animal</term><term>Dopamine Agents (toxicity)</term><term>Human</term><term>Humans</term><term>Mice</term><term>Mice, Knockout</term><term>Mice, Transgenic</term><term>Models</term><term>Models, Genetic</term><term>Nerve Tissue Proteins (genetics)</term><term>Oxidopamine (toxicity)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (genetics)</term><term>Risk Factors</term><term>Rotenone (toxicity)</term><term>Substantia Nigra (drug effects)</term><term>Synucleins</term><term>cell culture</term><term>disease models</term><term>transgenic mice</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Nerve Tissue Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Dopamine Agents</term><term>Oxidopamine</term><term>Rotenone</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Synucleins</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term><term>Cells, Cultured</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Apoptosis</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>DNA Mutational Analysis</term><term>Disease Models, Animal</term><term>Humans</term><term>Mice</term><term>Mice, Knockout</term><term>Mice, Transgenic</term><term>Models, Genetic</term><term>Risk Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Culture cellulaire</term><term>Homme</term><term>Modèle</term><term>Parkinson maladie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is a heterogenous disease likely to be caused by more than one specific aetiological factor. In rare familial cases of PD with similar clinical features to the idiopathic form of the disease, the underlying genetic cause has been identified. These PD‐associated genes have been manipulated to create animal and cell culture models of the disease that have helped to further our understanding of the pathogenesis of PD, particularly concerning causes of the selective loss of dopaminergic neurons at the molecular level. In addition, these models will aid the future development of rational therapeutic strategies. This study briefly reviews toxin‐induced models and the genetics of PD. It focuses on recently developed animal models of PD, as well as in vitro approaches to model the disease. © 2003 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Orth, Michael" sort="Orth, Michael" uniqKey="Orth M" first="Michael" last="Orth">Michael Orth</name></region><name sortKey="Tabrizi, Sarah J" sort="Tabrizi, Sarah J" uniqKey="Tabrizi S" first="Sarah J." last="Tabrizi">Sarah J. Tabrizi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004038 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004038 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:82545F26DC87C73EF84D8002EF2A4FE27E54BDB2
|texte= Models of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |